Abbott India Reports Strong Financial Performance
Abbott India, a leading pharmaceutical company in the largecap industry, has recently declared its financial results for the quarter ended September 2023. The company has shown a positive growth in its net sales, standalone net profit, and operating profit (PBDIT) excluding other income. The interest expenses have also decreased, leading to an improvement in the operating profit margin.
According to MarketsMOJO, a leading stock analysis platform, the stock call for Abbott India is 'Buy'. This is based on the company's strong financial performance in the quarter, with a growth of 1.02% in net sales and 7.82% in standalone net profit compared to the previous quarter. The operating profit (PBDIT) has also shown a growth of 7.29%, indicating the company's efficiency in managing its operations.
The company's financial score has also improved from 12 to 14 in the last three months, indicating a positive trend in its financial performance. The net sales for the quarter have been the highest in the last five quarters, and the operating profit (PBDIT) has also shown a positive trend. The operating profit margin has improved, indicating the company's efficiency in managing its costs.
Abbott India has also shown a positive trend in its profitability, with the highest profit before tax (PBT) and profit after tax (PAT) in the last five quarters. The company's earnings per share (EPS) have also increased, creating higher earnings for its shareholders. Additionally, the company has been distributing higher dividends to its shareholders from its profits.
However, the company's debtors turnover ratio has decreased, indicating a slower pace in settling its debtors. This is something that Abbott India may need to address in the future.
Overall, Abbott India has shown a strong financial performance in the quarter ended September 2023, with positive trends in its net sales, profitability, and efficiency. With a 'Buy' stock call from MarketsMOJO, the company seems to be on a positive trajectory in the pharma industry.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
{{text.big_txt}}
{{text .small_txt}}
{{dashverdictresult.dashboard.stock_details.short_name}}
SEND BY EMAIL
Register now to see if the stock’s characteristics match your investment style
Subscribe now to see if the stock's characteristics match your investment style
{{dashverdictresult.dashboard.risk_return_voltality.risk_type}}, {{dashverdictresult.dashboard.risk_return_voltality.return_type}}
| {{ value[0] }} | {{ value[1] }} | {{ value[2] }} | {{ value[3] }} |
| {{ value[0] }} | {{ value[1] }} | {{ value[2] }} | {{ value[3] }} |
Create your portfolio and know how much should this stock be in your portfolio
Subscribe now to know how much you should hold in this stock
We have found 2 better stocks that you can consider
{{dashverdictresult.dashboard.return_text}}
Investors Returns (3 years) –
| Period | 6M | 1Y | 2Y | 3Y |
| {{ keyd.val }} | ||||
| {{ keyd.val }} |
Quality: {{dashverdictresult.dashboard.dotsummary.q_txt}}
Valuation: {{dashverdictresult.dashboard.dotsummary.v_txt}}
Quarterly Financial Trend: {{dashverdictresult.dashboard.dotsummary.f_txt}}
Technicals: {{dashverdictresult.dashboard.dotsummary.tech_txt}}
Stock Info:
BSE – {{dashverdictresult.dashboard.stock_details.scripcode}}/ NSE – {{dashverdictresult.dashboard.stock_details.symbol}}
Market Cap – {{dashverdictresult.dashboard.priceinfo.mcap_class}} (Rs. {{dashverdictresult.dashboard.priceinfo.mcap| number :0}} cr)
Sector – {{dashverdictresult.dashboard.stock_details.ind_name}}
52 w H/L (Rs.) – {{dashverdictresult.dashboard.priceinfo.wk_high52}}/{{dashverdictresult.dashboard.priceinfo.wk_low52}}
Average vol (6M) – {{dashverdictresult.dashboard.priceinfo.vol}}
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
